Home

  Expert Committee on Specifications for Pharmaceutical Preparations

Expert Committee on Specifications for Pharmaceutical Preparations Global Regions WHO Regional websites Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific When autocomplete results are available use up and down arrows to review and enter to select. (...) Events 25 April – 2 May 2022 56th Expert Committee on Specifications for Pharmaceutical Preparations WHO Technical Report Series The WHO Expert Committee on Specifications for Pharmaceutical Preparations meets annually and their reports (WHO Technical Report Series) include all the adopted guidelines in the form of annexes. (...) WHO Technical Report Series 1033 Download Read More Previous reports 21 April 2020 WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fourth report WHO Expert Committee on Specifications for Pharmaceutical Preparations: fifty-fourth report 1 June 2019 TRS 1019 - 53rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 1019 - 53rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 16 May 2018 TRS 1001 - 52nd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 1001 - 52nd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 14 June 2017 TRS 1003 - 51st report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 1003 - 51st report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 2016 50th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 996 50th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 996 21 May 2015 49th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 992 49th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 992 1 June 2014 48th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 986 48th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 986 1 May 2013 47th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 981 47th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 981 1 June 2012 46th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 970 46th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 970 13 April 2011 Forty-fifth report of the WHO Expert Committee on specifications for pharmaceutical preparations Forty-fifth report of the WHO Expert Committee on specifications for pharmaceutical preparations 1 June 2010 44th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 957 44th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 957 1 June 2009 43rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 953 43rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 953 1 June 2008 TRS 948 - 42nd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 948 - 42nd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 2007 TRS 943 - 41st report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 943 - 41st report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 2005 TRS 929 - 39th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 929 - 39th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 2004 TRS 917- 38th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 917- 38th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 2003 TRS 908 - 37th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 908 - 37th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 2002 TRS 902 - 36th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 902 - 36th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 1999 TRS 885 - 35th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 885 - 35th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 1996 TRS 863 - 34th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 863 - 34th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 1993 TRS 834 - 33rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 834 - 33rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 1992 TRS 823 - 32nd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 823 - 32nd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 1990 31st report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 790 31st report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 790 1 June 1987 TRS 748 - 30th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 748 - 30th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 1984 TRS 704 - 29th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 704 - 29th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 1982 28th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 681 28th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 681 1 June 1980 27th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 645 27th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations - TRS, No. 645 1 June 1977 26th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 614 26th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 614 1 June 1975 25th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 567 25th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 567 1 June 1972 TRS 487 - 24th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations TRS 487 - 24th report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations 1 June 1971 23rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 463 23rd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 463 1 June 1969 22nd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 418 22nd report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 418 1 June 1965 21st report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 307 21st report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations -  TRS, No. 307 Regions Africa Americas Eastern Mediterranean Europe South-East Asia Western Pacific Policies Cyber security Ethics Permissions and licensing Preventing sexual exploitation Terms of use About us Careers Library Procurement Publications Frequently asked questions Contact us Subscribe to our newsletters Privacy Legal Notice © 2022 WHO

Score: 1086003.1 - https://www.who.int/teams/heal...or-pharmaceutical-preparations

  Microsoft Word - WTACCKHM3A3_LEG_38

A Prakas (Proclamation) of the Ministry of Health shall determine:  the formalities and conditions to apply for authorization to open, close or change of location of pharmacies, pharmaceutical manufacturing establishments, or companies involved in importing and exporting pharmaceuticals,  the formalities and conditions for application for a visa on the pharmaceutical log- book,  the formalities and technical conditions for the management and preservation of pharmaceuticals,  the formalities and conditions for advertising of pharmaceuticals, and  procedures for the production, import, export and trade of pharmaceuticals. (...) Authorization from the Ministry of Health shall be required for:  the opening, closing or changing of location of pharmacies, companies involved in importing and exporting pharmaceuticals or pharmaceutical manufacturing establishments.  businesses involved in importing and exporting pharmaceuticals,  importation, exportation and storage of pharmaceuticals and raw materials for the production of pharmaceuticals,  advertisement of pharmaceuticals. 2. (...) CHAPTER V: PENALTIES ARTICLE 10: Shall be penalized to a fine from 1,000,000 (one million) to 10,000,000 (ten million) riels and to a suspension of (activity) production or import, export or trade of pharmaceuticals for a period from one (1) month to three (3) months, or to either one of the above two punishment terms, exclusive of punishment for other offenses, for any person who: 1. advertised pharmaceuticals without authorization from the Ministry of Health. 2. who violated procedures and conditions for the production, import, export and trade of pharmaceuticals. 3. opened or changed locations of pharmacies, conducted businesses involved in importing and exporting pharmaceuticals or manufactured pharmaceuticals without proper authorization from the Ministry of Health. 4. produced, imported, exported or stored pharmaceuticals or pharmaceutical raw materials without proper authorization from the Ministry of Health. 5. sold pharmaceuticals without approval or keeping a log-book or sold those pharmaceuticals which are prohibited by the Ministry of Health.

Score: 1083554.6 - https://www.wto.org/english/th...e/khm_e/WTACCKHM3A3_LEG_38.pdf

  24mccollough_e

24mccollough_e WHO-WTO Workshop Presentation Oslo by Keith McCullough VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES Session V – Market Segmentation: Techniques,Actors & Incentives PURCHASE UNDERTAKINGS Including security and prevention of diversion VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES Business focus Pharmaceutical & Healthcare support services Consultancy Planning – Strategic and Operational Implementation – Turn key Process Management VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES COMED – Price Differentials Central Tendering Commission for Pharmaceutical and Surgical products and other medical requisites Two Markets – Public & Pvt VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES PHARMACEUTICAL/SURGICAL STOCK HOSPITAL Data PHARMACY,WARDS,OT’S PATIENT Care PREPACK Demand PHARMACY STORECLINIC Data PROVINCIAL DEPOT/s & sub-depots MANUFACTURER JIT IDEAL STOCK LEVELS Supply Chain Mananagement from Supplier to Patient VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES Main areas of competency & activity Patient clinical & pharmaceutical management systems Clinic management systems Hospital management systems Pharmacy management Procurement & logistics Distribution: direct and different carriers Depot management: physical and virtual Repacking unit set-up and management Training for all operational activities Health Facility design Financial management Management information reports and analysis Broad hands-on management expertise VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES Final Security BATCH NUMBER and any other distinguishing mark or electronic identifier VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES Wards,Theatres and Clinics Culture Threat Attitude Resource Problem Areas to be Addressed MAT VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES MAT & Diversion - Answer lSystems bases on Batch Number and Expiry Date lIntegrated Systems at Different Levels of the Supply Chain lRisk Management and Process Control Management VUNA HEALTHCARE LOGISTICS A THEBE COMPANY PHARMACEUTICAL AND HEALTHCARE SUPPORT SERVICES Thank YouThank YouThank YouThank YouThank YouThank YouThank YouThank You

Score: 1067784.2 - https://www.wto.org/english/tr...entations_e/24mccollough_e.pdf

  Sixth India Pharma Summit 2014-15

The theme for this year's deliberations was "Policy Landscape Reforms for Strengthening Indian Pharmaceutical Industry". Several important issues for the progress of the Indian pharmaceutical industry were deliberated, including critical verticals to foster access to pharmaceuticals at national and international level, promoting production and technology adoption in pharmaceutical enterprises for meeting national and global public health needs, regulatory issues and challenges for medical devices and diagnostics. (...) The Department of Pharmaceuticals (DOP) plans to launch 1000 Jan Aushadi stores in the country this year. (...) Senior officials including Dr VK Subburaj, Secretary, Department of Pharmaceuticals; Mr Sudhansh Pant, Joint Secretary, Department of Pharmaceuticals; Dr M Ariz Ahammed, Joint Secretary, Department of Pharmaceuticals; Dr Habil Khorakiwala, Chairman FICCI Life Sciences Council, Past President FICCI and Chairman Wockhardt Group; Mr.

Score: 1067317.3 - https://www.who.int/india/news...th-india-pharma-summit-2014-15

  1 HRH commitment pat

In addition, FIP and The Royal Pharmaceutical Society (GB) have agreed to launch a Global Pharmacy Workforce Observatory in 2014, that will contain all relevant data collected concerning the pharmaceutical workforce. 2. (...) Accessibility - Distribution of pharmaceutical HRH training insititutions by geographical location. - Distribution of pharmaceutical HRH by geographical location. - Density of pharmaceutical HRH for rural areas / density of HRH for urban areas in countries. Availability - Total number of pharmaceutical HRH (and density per 1,000 population). - Number of pharmaceutical students graduating each year. - Proportion of pharmaceutical students that are nationals.

Score: 1067058 - https://www.who.int/workforcea...alPharmaceuticalFederation.pdf

  225 16. THE PROTECTI

In fact, there are many different ways to exploit the right to use the pharmaceutical invention. The main ways of using a pharmaceutical invention are manufacturing pharmaceuticals: application of a patented process for manufacturing a pharmaceutical product; exploiting the utility of the protected pharmaceuticals or pharmaceuticals produced under the protected process; 10 ibid art 62. (...) Accordingly, the act of infringement of rights to pharmaceutical inventions are the same as rights to pharmaceutical invention within its protection term. (...) STATUS OF PROTECTION OF IP RIGHTS FOR PHARMACEUTICAL INVENTIONS IN VIETNAM A. REGISTRATION AND GRANT OF PROTECTION FOR PHARMACEUTICAL INVENTIONS As mentioned above, a pharmaceutical invention is always considered protected under Vietnamese law.

Score: 1065841.2 - https://www.wto.org/english/tr...s_e/2018/chapter_16_2018_e.pdf

  WTO | The WTO's Pharma Agreement

As a result of the 1994 Agreement and the subsequent reviews, participating members committed to eliminate customs duties and all other duties and charges not only on all finished pharmaceutical products, whether sold in bulk or in dosified packages for retail sale (paracetamol, antibiotics, vaccines, etc.), but also on over 7,000 pharmaceutical active ingredients and chemical components used in pharmaceutical supply chains. An indicative list of covered items is contained in JOB/MA/142 . Trade in pharmaceutical products International trade in pharmaceutical products has experienced dynamic growth since the adoption of the Pharma Agreement. (...) Trade in pharmaceutical active ingredients and chemical components has also grown steadily.

Score: 1062596.4 - https://www.wto.org/english/tr...ma_ag_e/pharma_agreement_e.htm

  - 2 - - 2 - [Governm

EITHER: [Name of Member] has no manufacturing capacities in the pharmaceutical sector. [Information on how this was established.] OR: [Name of Member] has found that its manufacturing capacity in the pharmaceutical sector is insufficient to meet its needs for this (or these) pharmaceutical product(s). (...) OPTIONAL, IF NO PATENTS IN FORCE: [The pharmaceutical product(s) is (are) not protected by patent in the territory of [name of Member]].

Score: 1060091.4 - https://www.wto.org/english/tr...31bis_model2notes_notifs_e.doc

  [Government letterhe

EITHER: [Name of Member] has no manufacturing capacities in the pharmaceutical sector. [Information on how this was established.] OR: [Name of Member] has found that its manufacturing capacity in the pharmaceutical sector is insufficient to meet its needs for this (or these) pharmaceutical product(s). (...) OPTIONAL, IF NO PATENTS IN FORCE: [The pharmaceutical product(s) is (are) not protected by patent in the territory of [name of Member]].

Score: 1060091.4 - https://www.wto.org/english/tr...31bis_model2notes_notifs_e.pdf

  April Contract Awards for publishing.xlsx

LTD 24 months + 24 months + 12 months renewable RFP-DAN-2021-503305 07/06/2021 Pharmaceuticals in Category 8 (Anaesthetics, Analgesics, Antidotes, Mental Health medicines) Time Bound LTA Mepro Pharmaceuticals Pvt Ltd 24 months + 24 months +12 months renewable RFP-DAN-2021-503305 07/06/2021 Pharmaceuticals in Category 8 (Anaesthetics, Analgesics, Antidotes, Mental Health medicines) Time Bound LTA Reyoung Pharmaceutical Co Ltd 24 months + 24 months + 12 months renewable RFP-DAN-2021-503305 07/06/2021 Pharmaceuticals in Category 8 (Anaesthetics, Analgesics, Antidotes, Mental Health medicines) Time Bound LTA Fresenius Kabi 24 months + 24 months + 12 months RFP-DAN-2021-503305 07/06/2021 Pharmaceuticals in Category 8 (Anaesthetics, Analgesics, Antidotes, Mental Health medicines) Time Bound LTA Morningside Pharmaceuticals Ltd. 24 months + 24 months +12 months renewable RFP-DAN-2021-503305 07/06/2021 Pharmaceuticals in Category 8 (Anaesthetics, Analgesics, Antidotes, Mental Health medicines) Time Bound LTA G.L. Pharma GmbH 24 months + 24 months + 12 months renewable RFP-DAN-2021-503305 07/06/2021 Pharmaceuticals in Category 8 (Anaesthetics, Analgesics, Antidotes, Mental Health medicines) Time Bound LTA SM Pharmaceuticals SDN. (...) Extension 24 months DAN-2019-RFP 503000 24/06/2019 Anti-infective pharmaceuticals category 2 - Extension Time Bound LTA Mepro Pharmaceuticals Pvt Ltd Extension 24 months DAN-2019-RFP 503000 24/06/2019 Anti-infective pharmaceuticals category 2 - Extension Time Bound LTA Macleods Pharmaceuticals Limited Extension 24 months DAN-2019-RFP 503000 24/06/2019 Anti-infective pharmaceuticals category 2 - Extension Time Bound LTA MILAN LABORATORIES (INDIA) PVT.

Score: 1059924 - https://www.unicef.org/supply/...contract-awards-april-2022.pdf